Two recent studies found a blood protein that could allow doctors to diagnose living patients for CTE, which is now only possible after death.
The neurological condition properly known as chronic traumatic encephalopathy is caused by repeated head trauma but currently can only be clinically diagnosed by examining the brain posthumously.
The newer of the two studies, published Thursday in the Journal of the American Medical Association, looked at blood samples taken from 21 former football players while alive who were then examined for CTE after death.
People were interested in these podcasts
Sixteen of the 21 players sampled (11 professionals, four college-level and one high-schooler) had higher-stage CTE while one pro and one high-schooler had lower-stage CTE, according to a release from Banner Health, which participated in the study along with Boston University researchers.
The study found the presence of a protein called endogenously cleaved microtubule-binding region tau (eMTBR-tau) to be significantly higher in the samples from the men with higher-stage CTE, compared to the two ex-players with lower-stage CTE and the remaining undiagnosed men in the sample (all three former college players), Banner Health said.
“I’m cautiously optimistic that we can really understand this finding and move it forward in the next five years or so,” co-author Michael Alosco, the co-director of clinical research at the Boston University CTE Center, told ESPN.
While an exact clinical diagnosis of chronic traumatic encephalopathy is only possible by an examination of brain tissue that cannot be done on a living person, the “punch-drunk” fighter has been known for a century. Tests for neurological and physical symptoms were how the diagnosis of dementia pugilistica (a scientific term coined in 1938) had been performed until recent years.
The other study, published in the Journal of the American Medical Association last week and conducted by researchers primarily from the Washington University in St. Louis medical school, looked at 229 people with brain diseases including both CTE and Alzheimer’s disease.
One of the people did not have Alzheimer’s disease, which is also associated with eMTBR-tau, but had a high level of the protein in the blood anyway. The researchers then found that the person had been diagnosed with higher-stage CTE following an autopsy, the school said in a release.
The researchers then tested 11 others who had been diagnosed with CTE posthumously, and found their levels of eMTBR-tau were higher than in healthy people and were higher the more severe the CTE diagnosis was.
“This is not going to be a standalone biomarker. But if someone has a history of repeated head injury, tests negative for Alzheimer’s, and this biomarker comes up, it might be CTE,” co-author Chihiro Sato said in the school’s release.

Please read our comment policy before commenting.